Many MedTech companies dream of a single registration process for the entire Mercosur market, including giants like Brazil and Argentina. Is this a reality, or just a regulatory myth? This episode of LATAM MedTech Insights dives deep into the current state of regulatory harmonization in the region. We uncover the practical challenges and strategic opportunities that exist today. While Mercosur is moving towards a unified framework, the reality on the ground is a complex patchwork of national adoptions and lingering local requirements. We break down why you can't use a single dossier and what this means for your market access strategy, timelines, and budget. **Key Questions Answered in this Episode:** * Is there truly a single registration dossier for all of Mercosur? * How does Brazil's ANVISA registration differ from Argentina's ANMAT, even under new Mercosur rules? * What is the most significant non-tariff barrier to entry in Brazil for medical devices? * Which specific GMC resolution is changing the game for MedTech in the region? * Why is a local, in-country representative still non-negotiable in each market? * How are countries like Uruguay and Paraguay adopting these harmonized standards? * What are the common pitfalls that delay product launches in LATAM? * How can you leverage one country's approval to potentially speed up the process in another? At Pure Global, we specialize in turning these complex regulatory challenges into clear market access strategies. Our team offers end-to-end solutions, from acting as your local representative in Brazil and Argentina to compiling technical dossiers with AI-powered efficiency. Don't let regulatory hurdles slow your growth in LATAM. Contact us for a consultation at [email protected] or visit https://pureglobal.com/ to learn more.